Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.

@article{Hornberger2006CosteffectivenessOP,
  title={Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.},
  author={John C. Hornberger and Francesca J. Torriani and Douglas T. Dieterich and Norbert Br{\"a}u and Mark S Sulkowski and Maribel Rodr{\'i}guez Torres and Jesse Green and Kavita Patel},
  journal={Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology},
  year={2006},
  volume={36 4},
  pages={283-91}
}
BACKGROUND A multinational trial (APRICOT) showed that peginterferon alfa-2a (40kDa) plus ribavirin is efficacious for treatment of HIV-HCV co-infection. The cost-effectiveness of treating these patients with peginterferon alfa-2a/ribavirin has yet to be explored from a US societal perspective. OBJECTIVE To predict the cost-effectiveness of peginterferon alfa-2a/ribavirin with interferon/ribavirin (IFN/RBV) or no treatment in HIV-HCV co-infected patients. STUDY DESIGN A Markov model was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.

Similar Papers

Loading similar papers…